Glioblastoma research 2006-2010: Pattern of citation and systematic review of highly cited articles

Clinical Neurology and Neurosurgery

Volumn 114, Issue 9, 2012, Pages 1207-1210

  Nieder, Carsten ^a,b   Astner, Sabrina T ^c   Grosu, Anca L ^d  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Citation; Glioblastoma; Grade IV glioma; Malignant glioma; Research evaluation

Indexed keywords

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RESEARCH; CITATION ANALYSIS; GLIOBLASTOMA; HUMAN; PATHOGENESIS; REVIEW; STEM CELL; SYSTEMATIC REVIEW;

ANIMALS; BIBLIOMETRICS; BRAIN NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; GENOMICS; GLIOBLASTOMA; HUMANS; JOURNAL IMPACT FACTOR; META-ANALYSIS AS TOPIC; NEOPLASTIC STEM CELLS; PUBLISHING; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84866893673     PISSN: 03038467     EISSN: 18726968     Source Type: Journal    
DOI: 10.1016/j.clineuro.2012.03.049     Document Type: Review

References (58)

1. C. Nieder, A.L. Grosu, M.P. Mehta, N. Andratschke, and M. Molls Treatment of malignant gliomas: radiotherapy, chemotherapy and integration of new targeted agents Expert Rev Neurother 4 2004 691 703
2. P.Y. Wen, and S. Kesari Malignant gliomas in adults N Engl J Med 359 2008 492 507
3. R. Stupp, M.E. Hegi, M.J. van den Bent, W.P. Mason, M. Weller, and R.O. Mirimanoff Changing paradigms - an update on the multidisciplinary management of malignant glioma Oncologist 11 2006 165 180
4. D.A. Reardon, J.N. Rich, H.S. Friedman, and D.D. Bigner Recent advances in the treatment of malignant astrocytoma J Clin Oncol 24 2006 1253 1265
5. A.M. Stark, J. van de Bergh, J. Hedderich, H.M. Mehdorn, and A. Nabavi Glioblastoma: clinical characteristics, prognostic factors and survival in 492 patients Clin Neurol Neurosurg 2012 [epub, Feb 27]
6. V. Kumar, S. Upadhyay, and B. Medhi Impact of the impact factor in biomedical research: its use and misuse Singapore Med J 50 2009 752 755
7. N.S. Young, J.P.A. Ioannidis, and O. Al-Ubaydli Why current publication practices may distort science PLoS Med 5 2008 e201
8. Z. Kanaan, S. Galandiuk, M. Abby, K.V. Shannon, D. Dajani, and N. Hicks The value of lesser-impact-factor surgical journals as a source of negative and inconclusive outcomes reporting Ann Surg 253 2011 619 623
9. P. Owlia, M. Vasei, B. Goliaei, and I. Nassiri Normalized impact factor (NIF): an adjusted method for calculating the citation rate of biomedical journals J Biomed Inform 44 2011 216 220
10. V. Durieux, and P.A. Gevenois Bibliometric indicators: quality measurements of scientific publication Radiology 255 2010 342 351
11. F. Radicchi, S. Fortunato, and C. Castellano Universality of citation distributions: toward an objective measure of scientific impact Proc Natl Acad Sci U S A 105 2008 17268 17272
12. P. Vinkler Relations of relative scientometric indicators Scientometrics 58 2003 687 694
13. S. Bao, Q. Wu, R.E. McLendon, Y. Hao, Q. Shi, and A.B. Hjelmeland Glioma stem cells promote radioresistance by preferential activation of the DNA damage response Nature 444 2006 756 760 [cited 1130 times]
14. G. Liu, X. Yuan, Z. Zeng, P. Tunici, H. Ng, and I.R. Abdulkadir Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma Mol Cancer 5 2006 67 [cited 459 times]
15. J. Lee, S. Kotliarova, Y. Kotliarov, A. Li, Q. Su, and N.M. Donin Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines Cancer Cell 9 2006 391 403 [cited 436 times]
16. H.S. Phillips, S. Kharbanda, R. Chen, W.F. Forrest, R.H. Soriano, and T.D. Wu Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis Cancer Cell 9 2006 157 173 [cited 423 times]
17. S.G. Piccirillo, B.A. Reynolds, N. Zanetti, G. Lamorte, E. Binda, and G. Broggi Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells Nature 444 2006 761 765 [cited 382 times]
18. D.N. Louis, H. Ohgaki, O.D. Wiestler, W.K. Cavenee, P.C. Burger, and A. Jouvet The 2007 WHO classification of tumours of the central nervous system Acta Neuropathol (Berl) 114 2007 97 109 [cited 986 times]
19. T.T. Batchelor, A.G. Sorensen, E. di Tomaso, W.T. Zhang, D.G. Duda, and K.S. Cohen AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 11 2007 83 95 [cited 585 times]
20. J.J. Vredenburgh, A. Desjardins, J.E. Herndon II, J. Marcello, D.A. Reardon, and J.A. Quinn Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 2007 4722 4729 [cited 416 times]
21. F.B. Furnari, T. Fenton, R.M. Bachoo, A. Mukasa, J.M. Stommel, and A. Stegh Malignant astrocytic glioma: genetics, biology, and paths to treatment Genes Dev 21 2007 2683 2710 [cited 350 times]
22. D. Beier, P. Hau, M. Proescholdt, A. Lohmeier, J. Wischhusen, and P.J. Oefner CD133+ and CD133- glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles Cancer Res 67 2007 4010 4015 [cited 343 times]
23. R. McLendon, A. Friedman, D. Bigner, E.G. van Meir, D.J. Brat, and G.M. Mastrogianakis Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 455 2008 1061 1068 [cited 908 times]
24. D.W. Parsons, S. Jones, X. Zhang, J.C.H. Lin, R.J. Leary, and P. Angenendt An integrated genomic analysis of human glioblastoma multiforme Science 321 2008 1807 1812 [cited 877 times]
25. I. Ben-Porath, M.W. Thomson, V.J. Carey, R. Ge, G.W. Bell, and A. Regev An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors Nat Genet 40 2008 499 507 [cited 413 times]
26. A.D. Norden, G.S. Young, K. Setayesh, A. Muzikansky, R. Klufas, and G.L. Ross Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology 70 2008 779 787 [cited 262 times]
27. M. Pàez-Ribes, E. Allen, J. Hudock, T. Takeda, H. Okuyama, and F. Viñals Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 2009 220 231 [cited 496 times]
28. H. Yan, D.W. Parsons, G. Jin, R. McLendon, B.A. Rasheed, and W. Yuan IDH1 and IDH2 mutations in gliomas N Engl J Med 360 2009 765 773 [cited 446 times]
29. R. Stupp, M.E. Hegi, W.P. Mason, M.J. van den Bent, M.J. Taphoorn, and R.C. Janzer Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 2009 459 466 [cited 398 times]
30. H.S. Friedman, M.D. Prados, P.Y. Wen, T. Mikkelsen, D. Schiff, and L.E. Abrey Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 2009 4733 4740 [cited 324 times]
31. T.N. Kreisl, L. Kim, K. Moore, P. Duic, C. Royce, and I. Stroud Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 27 2009 740 745 [cited 250 times]
32. R.G. Verhaak, K.A. Hoadley, E. Purdom, V. Wang, Y. Qi, and M.D. Wilkerson Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 17 2010 98 110 [cited 254 times]
33. P.Y. Wen, D.R. Macdonald, D.A. Reardon, T.F. Cloughesy, A.G. Sorensen, and E. Galanis Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group J Clin Oncol 28 2010 1963 1972 [cited 128 times]
34. H. Noushmehr, D.J. Weisenberger, K. Diefes, H.S. Phillips, K. Pujara, and B.P. Berman Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma Cancer Cell 17 2010 510 522 [cited 118 times]
35. R. Chen, M.C. Nishimura, S.M. Bumbaca, S. Kharbanda, W.F. Forrest, and I.M. Kasman A hierarchy of self-renewing tumor-initiating cell types in glioblastoma Cancer Cell 17 2010 362 375 [cited 79 times]
36. M. Weller, R. Stupp, G. Reifenberger, A.A. Brandes, M.J. van den Bent, and W. Wick MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nature Rev Neurol 6 2010 39 51 [cited 79 times]
37. S. Kunwar, S. Chang, M. Westphal, M. Vogelbaum, J. Sampson, and G. Barnett Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma Neurooncology 12 2010 871 881 [cited 32 times]
38. G.G. Grabenbauer, K.D. Gerber, O. Ganslandt, A. Richter, G. Klautke, and J. Birkmann Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme Int J Radiat Oncol Biol Phys 75 2009 164 169 [cited 4 times]
39. G. Dresemann, M. Weller, M.A. Rosenthal, U. Wedding, W. Wagner, and E. Engel Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide J Neurooncol 96 2010 393 402 [cited 16 times]
40. J.L. Clarke, F.M. Iwamoto, J. Sul, K. Panageas, A.B. Lassman, and L.M. DeAngelis Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma J Clin Oncol 7 2009 3861 3867 [cited 35 times]
41. M. Kocher, P. Frommolt, S.K. Borberg, U. Rühl, M. Steingräber, and M. Niewald Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma Strahlenther Onkol 184 2008 572 579 [cited 15 times]
42. ® fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial Lasers Med Sci 23 2008 361 367 [cited 31 times]
43. J.C. Buckner, K.V. Ballman, J.C. Michalak, G.V. Burton, T.L. Cascino, and P.J. Schomberg Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 trials J Clin Oncol 24 2006 3871 3879 [cited 17 times]
44. F. Imbesi, E. Marchioni, E. Benericetti, F. Zappoli, A. Galli, and M. Corato A randomized phase III study: comparison between intravenous and intraarterial ACNU administration in newly diagnosed primary glioblastomas Anticancer Res 26 2006 553 558 [cited 7 times]
45. V.A. Levin, S. Phuphanich, W.K. Yung, P.A. Forsyth, R. Del Maestro, and J.R. Perry Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation J Neurooncol 78 2006 295 302 [cited 37 times]
46. P.W. Willems, M.J. Taphoorn, H. Burger, J.W. Van Der Sprenkel, and C.A. Tulleken Effectiveness of neuronavigation in resecting solitary intracerebral contrast-enhancing tumors: a randomized controlled trial J Neurosurg 104 2006 360 368 [cited 25 times]
47. F. Keime-Guibert, O. Chinot, L. Taillandier, S. Cartalat-Carel, M. Frenay, and G. Kantor Radiotherapy for glioblastoma in the elderly N Engl J Med 356 2007 1527 1535 [cited 153 times]
48. ® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial Acta Neurochir (Wien) 148 2006 269 275 [cited 119 times]
49. D.A. Reardon, K.L. Fink, T. Mikkelsen, T.F. Cloughesy, A. O'Neill, and S. Plotkin Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme J Clin Oncol 26 2008 5610 5617 [cited 113 times]
50. M.J. Van den Bent, A.A. Brandes, R. Rampling, M.C. Kouwenhoven, J.M. Kros, and A.F. Carpentier Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034 J Clin Oncol 27 2009 1268 1274 [cited 90 times]
51. J. Sotelo, E. Briceño, and M.A. López-González Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial Ann Intern Med 144 2006 337 343 [cited 55 times]
52. W. Wick, V.K. Puduvalli, M.C. Chamberlain, M.J. van den Bent, A.F. Carpentier, and L.M. Cher Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma J Clin Oncol 28 2010 1168 1174 [cited 43 times]
53. D. Kondziolka Citation measures in stereotactic radiosurgery: publication across a discipline Stereotact Funct Neurosurg 89 2011 56 61
54. N.A. Patsopoulos, A.A. Analatos, and J.P. Ioannidis Relative citation impact of various study designs in the health sciences JAMA 293 2005 2362 2366
55. M.J. Stringer, M. Sales-Pardo, and L.A. Nunes Amaral Effectiveness of journal ranking schemes as a tool for locating information PLoS One 3 2008 e1683
56. M.J. Stringer, M. Sales-Pardo, and L.A. Nunes Amaral Statistical validation of a global model for the distribution of the ultimate number of citations accrued by papers published in a scientific journal J Am Soc Inf Sci Technol 61 2010 1377 1385
57. A.V. Kulkarni, B. Aziz, I. Shams, and J.W. Busse Author self-citation in the general medicine literature PLoS One 6 2011 e20885
58. A. Natalwala, V. Bharkhada, G. Noel, and G. Cruickshank Comparison of time taken from initial presentation to histological diagnosis of glioblastoma multiforme (GBM) in Birmingham, United Kingdom and Strasbourg, France Clin Neurol Neurosurg 113 2011 358 361